

Jose Luis Ramirez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7873601/publications.pdf>

Version: 2024-02-01

31
papers

7,533
citations

516561

16
h-index

677027

22
g-index

31
all docs

31
docs citations

31
times ranked

10249
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. Journal of Clinical Oncology, 2019, 37, TPS501-TPS501.	0.8	0
2	Monitoring <i>EGFR</i> -T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	0.8	8
3	A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.. Journal of Clinical Oncology, 2018, 36, TPS4593-TPS4593.	0.8	0
4	Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. Journal of the National Cancer Institute, 2017, 109, .	3.0	128
5	Activation of signal transducer and activator of transcription 3 (STAT3) signaling in EGFR mutant non-small-cell lung cancer (NSCLC). Oncotarget, 2017, 8, 47305-47316.	0.8	40
6	Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. Journal of Neuro-Oncology, 2016, 127, 569-579.	1.4	40
7	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Scientific Reports, 2015, 5, 17499.	1.6	55
8	The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies. Nature Genetics, 2015, 47, 250-256.	9.4	434
9	Leishmania major Telomerase TERT Protein Has a Nuclear/Mitochondrial Eclipsed Distribution That Is Affected by Oxidative Stress. Infection and Immunity, 2015, 83, 57-66.	1.0	11
10	DNA repair- and apoptosis-pathways to regulate response to chemo-radiotherapy (CRT) in patients (p) with locally advanced head and neck cancer (HNC).. Journal of Clinical Oncology, 2015, 33, e17025-e17025.	0.8	0
11	RAP80 mRNA expression impact on sporadic high-grade serous ovarian cancer survival.. Journal of Clinical Oncology, 2015, 33, e16571-e16571.	0.8	0
12	BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).. Journal of Clinical Oncology, 2015, 33, e19078-e19078.	0.8	0
13	Validation of ERCC1 (E1) for response prediction to platinum-gemcitabine.. Journal of Clinical Oncology, 2015, 33, 8036-8036.	0.8	0
14	IDH 1 /2 status and low grade gliomas (LGG): Correlation with outcome upfront Pignatti criteria and molecular profile in a retrospective analysis of a single-centre cohort from Spain.. Journal of Clinical Oncology, 2015, 33, 2046-2046.	0.8	0
15	Non-Small Cell Lung Cancer (NSCLC) harboring Epidermal Growth Factor Receptor mutations (EGFR-m) and breast cancer (BC): A retrospective analysis of a single institution.. Journal of Clinical Oncology, 2015, 33, e19112-e19112.	0.8	0
16	Study of the oipA genetic diversity and EPIYA motif patterns in <i>cagA</i> -positive <i>Helicobacter pylori</i> strains from Venezuelan patients with chronic gastritis. Microbial Pathogenesis, 2014, 76, 26-32.	1.3	16
17	Clinical Validation of a PCR Assay for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer: Retrospective Testing of Specimens from the EURTAC Trial. PLoS ONE, 2014, 9, e89518.	1.1	32
18	Genotyping of <i>Helicobacter pylori</i> virulence-associated genes shows high diversity of strains infecting patients in western Venezuela. International Journal of Infectious Diseases, 2013, 17, e750-e756.	1.5	28

#	ARTICLE	IF	CITATIONS
19	Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2012, 13, 239-246.	5.1	4,943
20	First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. <i>Lung Cancer</i> , 2011, 72, 84-91.	0.9	37
21	Characterization of <i>Trypanosoma cruzi</i> telomerase. <i>Acta Tropica</i> , 2011, 120, 173-178.	0.9	2
22	Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients. <i>Clinical and Translational Oncology</i> , 2011, 13, 677-685.	1.2	34
23	A heat-activated and thermoresistant telomerase activity in <i>Leishmania major</i> Friedlin. <i>Acta Tropica</i> , 2009, 111, 86-89.	0.9	7
24	Translational research in glioblastoma multiforme: molecular criteria for patient selection. <i>Future Oncology</i> , 2008, 4, 219-228.	1.1	16
25	DNA Repair and Mitotic Checkpoint Genes as Potential Predictors of Chemotherapy Response in Non-Small-Cell Lung Cancer. , 2008, , 231-247.		1
26	14-3-3 β Methylation in Pretreatment Serum Circulating DNA of Cisplatin-Plus-Gemcitabine-Treated Advanced Non-Small-Cell Lung Cancer Patients Predicts Survival: The Spanish Lung Cancer Group. <i>Journal of Clinical Oncology</i> , 2005, 23, 9105-9112.	0.8	114
27	The Genome Sequence of <i>Trypanosoma cruzi</i> , Etiologic Agent of Chagas Disease. <i>Science</i> , 2005, 309, 409-415.	6.0	1,273
28	Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. <i>Cancer Letters</i> , 2003, 193, 207-216.	3.2	115
29	O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. <i>Clinical Cancer Research</i> , 2003, 9, 1461-8.	3.2	111
30	Cloning and Characterization of <i>Leishmania donovani</i> Telomeres. <i>Experimental Parasitology</i> , 2000, 94, 248-258.	0.5	33
31	Organization of telomeric and sub-telomeric regions of chromosomes from the protozoan parasite <i>Trypanosoma cruzi</i> . <i>Molecular and Biochemical Parasitology</i> , 1999, 100, 173-183.	0.5	55